What is it about?
This randomized, open-label study evaluated the additional benefits of the synbiotic Prodefen® in the clinical management of acute diarrhea of suspected viral origin in children between 6 months and 12 years of age
Featured Image
Read the Original
This page is a summary of: A Multicenter, Prospective, Randomized Controlled Trial to Evaluate the Additional Benefit of a Multistrain Synbiotic (Prodefen®) in the Clinical Management of Acute Viral Diarrhea in Children, Global Pediatric Health, March 2016, SAGE Publications,
DOI: 10.1177/2333794x16679587.
You can read the full text:
Contributors
The following have contributed to this page
